Abstract:Invasive fungal infections caused by drug-resistant organisms are an emerging threat to heavily immunosuppressed patients with hematological malignancies. Modern early antifungal treatment strategies, such as prophylaxis and empirical and preemptive therapy, result in long-term exposure to antifungal agents, which is a major driving force for the development of resistance. The extended use of central venous catheters, the nonlinear pharmacokinetics of certain antifungal agents, neutropenia, other forms of intense immunosuppression, and drug toxicities are other contributing factors. The widespread use of agricultural and industrial fungicides with similar chemical structures and mechanisms of action has resulted in the development of environmental reservoirs for some drug-resistant fungi, especially azole-resistant Aspergillus species, which have been reported from four continents. The majority of resistant strains have the mutation TR34/L98H, a finding suggesting that the source of resistance is the environment. The global emergence of new fungal pathogens with inherent resistance, such as Candida auris, is a new public health threat. The most common mechanism of antifungal drug resistance is the induction of efflux pumps, which decrease intracellular drug concentrations. Overexpression, depletion, and alteration of the drug target are other mechanisms of resistance. Mutations in the ERG11 gene alter the protein structure of C-demethylase, reducing the efficacy of antifungal triazoles. Candida species become echinocandin-resistant by mutations in FKS genes. A shift in the epidemiology of Candida towards resistant non-albicans Candida spp. has emerged among patients with hematological malignancies. There is no definite association between antifungal resistance, as defined by elevated minimum inhibitory concentrations, and clinical outcomes in this population. Detection of genes or mutations conferring resistance with the use of molecular methods may offer better predictive values in certain cases. Treatment options for resistant fungal infections are limited and new drugs with novel mechanisms of actions are needed. Prevention of resistance through antifungal stewardship programs is of paramount importance.

Research Progress on Antifungal Chemotherapy and Photodynamic Therapy Drug

Progress on pharmacokinetics/pharmacodynamics of antimicrobial agents

Photodynamic Therapy in the Treatment of Superficial Mycoses: An Evidence-based Evaluation

Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review

Drug repurposing strategies in the development of potential antifungal agents

Advancements and challenges in antifungal therapeutic development

Old and new strategies in therapy and diagnosis against fungal infections

Promising immunotherapeutic targets for treating candidiasis

Related mechanisms and research progress in straight back syndrome

New antifungal strategies: drug combination and co-delivery

The progress in antifungal resistance of pathogenic Aspergillus spp.

Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations

Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies

Cutaneous and subcutaneous fungal infections: recent developments on host-fungus interactions

A Brief Introduction to Several Novel Antifungal Drugs

Analysis of antifungal susceptibility in vitro and fungi distribution in clinics

Advances in Research on Antifungal Effect of Natural Plant Components

Advances in PK/PD studies of antifungals

Advances on the research and development of new antimicrobial agents

Recent Advances in Photodynamic Therapy against Fungal Keratitis

Nanomaterial-based therapeutics for enhanced antifungal therapy